Spinifex Pharmaceuticals' EMA401 Named One of the Top Ten Neuroscience Projects to Watch

Spinifex Pharmaceuticals' EMA401 NamedSpinifex Pharmaceuticals' EMA401 Named One of the Top Ten Neuroscience Projects to Watch PR Newswire MELBOURNE, Australia, October 18, 2013 Company to present at Elsevier Business Intelligence's 2013 Therapeutic Area Partnerships Spinifex Pharmaceuticals, an Australian pain drug development company, today announces that CEO Tom McCarthy will present at Elsevier Business Intelligence's 2013 Therapeutic Area Partnerships (18-20 November in Boston, USA). Dr McCarthy's presentation will give an overview of the Company's lead candidate, EMA401, which is a novel angiotensin II type 2 (AT )receptor2 antagonist under development as a potential first-in-class oral treatment for chronic pain without CNS side effects. EMA401 has been selected as an Elsevier Top Ten Neuroscience Project to Watch, representing one of the most attractive investment opportunities in the industry. The rigorous judging criteria included unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities and potential for new opportunities beyond initial indications and corporate stability. Spinifex Pharmaceuticals has reported positive headline results from a Phase 2 clinical trial of EMA401 in post herpetic neuralgia, a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.